Antisense oligonucleotide modulation of raf gene expression
AssigneeIsis Pharmaceuticals, Inc.
InventorBrett P. Monia
Life of this patent
Estimating the term…
Abstract
Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.
Claims2
A method of treating pancreatic, renal cell, colon or bladder cancer comprising administering to a human or cells thereof a therapeutically effective amount of an oligonucleotide 8 to 50 nucleotides in length which is targeted to mRNA encoding human c-raf (SEQ ID NO:
- 64), wherein said oligonucleotide comprises SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.